{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-018808","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2025-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.390170+00:00","generated_at":"2026-05-18T06:58:40.096818+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Calidi shareholders approve reverse stock split and 3M-share equity plan increase","bullets":["Elected James Schoeneck (6.5M for) and George Peoples (6.6M for) as Class II directors.","Ratified CBIZ CPAs P.C. as auditor for FY2025 (15.6M for, 1.3M against).","Approved reverse stock split ratio of 1:2 to 1:19, with board discretion on exact ratio.","Approved amendment to 2023 Equity Plan increasing authorized shares from 393,780 to 3,393,780.","All four proposals passed; quorum of 53.26% of shares represented."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-018808","json":"https://secwatch.observer/filing/0001641172-25-018808.json","markdown":"https://secwatch.observer/filing/0001641172-25-018808.md","text":"https://secwatch.observer/filing/0001641172-25-018808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225018808/0001641172-25-018808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225018808/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:58:40.096818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}